NKGN NKGen Biotech Corp: Earnings per share for the last 12 months

NKGen Biotech, Inc. (NKGN) develops cell therapies for neurodegenerative pathologies in the US and Korea. The 12-month YoY change in net income per share reflects profitability dynamics, with the current figure standing at . Growth is driven by NK-cell cultivation patents and the implementation of robotic systems to accelerate drug trials for Alzheimer's disease.
NKGN (NKGen Biotech Inc): analytical breakdowns and indicator data

Earnings per share dynamics serve as a key indicator of a business's fundamental value. This metric measures the percentage change in net income over the last twelve months relative to the same period last year. By analyzing current EPS YoY TTM growth rates, an investor assesses the real efficiency of capital management. For NKGen Biotech, Inc. (NKGN), such fluctuations reflect the impact of colossal R&D expenditures. High investments in Alzheimer's disease therapy temporarily dominate current profitability.